Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
1995 1
1996 3
1997 2
1998 2
1999 3
2000 1
2001 1
2002 2
2003 2
2004 2
2006 3
2007 9
2008 12
2009 8
2010 11
2011 18
2012 21
2013 17
2014 19
2015 19
2016 14
2017 15
2018 16
2019 17
2020 6
2021 9
2022 3
2023 5
2024 7
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

211 results

Results by year

Filters applied: . Clear all
Page 1
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Moreau P, et al. N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282. N Engl J Med. 2016. PMID: 27119237 Free article. Clinical Trial.
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R. Ohtake S, et al. Among authors: nakaseko c. Blood. 2011 Feb 24;117(8):2358-65. doi: 10.1182/blood-2010-03-273243. Epub 2010 Aug 6. Blood. 2011. PMID: 20693429 Free article. Clinical Trial.
Detection of clonal plasma cells in POEMS syndrome using multiparameter flow cytometry.
Ishii A, Tsukamoto S, Mimura N, Miyamoto-Nagai Y, Isshiki Y, Matsui S, Nakao S, Shibamiya A, Hino Y, Kayamori K, Oshima-Hasegawa N, Muto T, Takeda Y, Suichi T, Misawa S, Ohwada C, Yokote K, Kuwabara S, Nakaseko C, Takamatsu H, Sakaida E. Ishii A, et al. Among authors: nakaseko c. Sci Rep. 2024 May 6;14(1):10362. doi: 10.1038/s41598-024-61034-1. Sci Rep. 2024. PMID: 38710832 Free PMC article.
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.
Matsumura I, Ohtake S, Atsuta Y, Kurata M, Minami Y, Takahashi N, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Ono T, Okada M, Tauchi T, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Asou N, Naoe T, Kiyoi H, Miyazaki Y. Matsumura I, et al. Among authors: nakaseko c. Blood Adv. 2024 Oct 22;8(20):5237-5247. doi: 10.1182/bloodadvances.2024012655. Blood Adv. 2024. PMID: 38968156 Free PMC article. Clinical Trial.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
Clinical impact of airflow obstruction after allogeneic hematopoietic stem cell transplantation.
Nakao S, Tsukamoto S, Takeda Y, Ohwada C, Ri C, Izumi S, Kamata Y, Matsui S, Shibamiya A, Ishii A, Takaishi K, Takahashi K, Shiko Y, Oshima-Hasegawa N, Muto T, Mimura N, Yokote K, Nakaseko C, Sakaida E. Nakao S, et al. Among authors: nakaseko c. Int J Hematol. 2024 Oct;120(4):501-511. doi: 10.1007/s12185-024-03831-y. Epub 2024 Aug 27. Int J Hematol. 2024. PMID: 39190255 Free PMC article.
Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort.
Ohwada C, Sakaida E, Takeda Y, Doki N, Igarashi A, Onizuka M, Toyosaki M, Tanaka M, Tachibana T, Kataoka K, Kato J, Fujisawa S, Kato S, Nakasone H, Naganuma K, Saitoh T, Shono K, Hagihara M, Saito T, Usuki K, Mori T, Nakaseko C, Okamoto S, Kanda Y. Ohwada C, et al. Among authors: nakaseko c. Int J Hematol. 2024 Sep;120(3):347-355. doi: 10.1007/s12185-024-03813-0. Epub 2024 Jul 17. Int J Hematol. 2024. PMID: 39017858
Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.
Matsushita K, Kitamura K, Rahmutulla B, Tanaka N, Ishige T, Satoh M, Hoshino T, Miyagi S, Mori T, Itoga S, Shimada H, Tomonaga T, Kito M, Nakajima-Takagi Y, Kubo S, Nakaseko C, Hatano M, Miki T, Matsuo M, Fukuyo M, Kaneda A, Iwama A, Nomura F. Matsushita K, et al. Among authors: nakaseko c. Oncotarget. 2015 Mar 10;6(7):5102-17. doi: 10.18632/oncotarget.3244. Oncotarget. 2015. PMID: 25671302 Free PMC article.
211 results